



Governor  
Douglas Ducey

**ARIZONA BOARD OF OSTEOPATHIC EXAMINERS  
IN MEDICINE AND SURGERY**

9535 EAST DOUBLETREE RANCH ROAD  
SCOTTSDALE, ARIZONA 85258-5572  
PH (480) 657-7703 | FX (480) 657-7715  
www.azdo.gov | questions@azdo.gov

**Board Members:**  
Scott A. Steingard, D.O., Pres.  
Douglas Cunningham, D.O., V.P.  
Gary Erbstoesser, D.O.  
Jerry G. Landau, J.D.  
Martin Reiss, D.O.  
Lew Riggs, Ed.D.  
Vas Sabeeh, D.O.

**Executive Director**  
Jenna Jones

October 30, 2015

Dear Doctor:

State law requires every Arizona medical practitioner who possesses a Drug Enforcement Administration ("DEA") permit to also hold a Controlled Substances Prescription Monitoring Program ("CSPMP") registration issued by the Arizona State Board of Pharmacy ("Pharmacy Board") A.R.S. §32-2606. The failure of a medical practitioner to obtain a CSPMP registration may result in disciplinary action by the practitioner's licensing board. See A.R.S. § 32-2607.

Arizona Revised Statutes § 32-3219, mandates the Arizona State Board of Osteopathic Examiners in Medicine and Surgery ("Osteopathic Board") to notify the Pharmacy Board of newly-licensed physicians who intend to apply for a DEA permit as well as physicians who renew their licenses.

The Osteopathic Board is also required to submit to the Pharmacy Board information to assist the Pharmacy Board in the registration of medical professionals for the CSPMP. To facilitate the Osteopathic Board's collection of this information please complete the enclosed form and submit it to the Osteopathic Board along with your license application/renewal application.

If you are completing your license renewal online, please fax, mail or email the form to our office (information above) within 20 days after submitting your renewal.

If you have any questions regarding this letter or the attached form, please contact Dean Wright at the Pharmacy Board, 602-771-2744. Mr. Wright is the Prescription Monitoring Program Director with the Arizona Board of Pharmacy and is responsible for the administration of the Controlled Substances Prescription Monitoring Program.

Sincerely,

Jenna Jones  
Executive Director

